LABCORP HOLDINGS INC. 10-Q

ITEM 5. OTHER INFORMATION Insider Adoption or Termination of Trading Arrangements: During the quarter ended March 31, 2026, none of the Company’s directors or officers informed it of the adoption, modification or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, except as described in the table below: Name and Title Date Adopted Character of Trading Agreement Aggregate Number of Shares of Common Stock to be (Sold) Purchased Pursuant to Trading Agreement Expiration Date Kathryn W. Kyle March 9, 2026 Rule 10b5-1 Trading Arrangement ( 1,633 ) (1)(2) April 9, 2027 (3) Executive Vice President, Chief Legal Officer and Corporate Secretary Bryan T. Vaughn March 8, 2026 Rule 10b5-1 Trading Arrangement ( 2,813 ) (1) May 7, 2027 (3) Executive Vice President, Diagnostics (1) The figure presented represents the shares to be sold on the vesting of equity awards and may vary subject to the achievement of certain performance conditions and/or shares to be withheld for tax purposes. (2) Ms. Kyle’s plan provides for the sale of up to 195 shares of Common Stock previously acquired from an equity award vesting event. (3) This trading arrangement permits transactions through the completion of all sales on the respective order entry date. 30 TABLE OF CONTENTS ITEM 6. EXHIBITS (a) 10.1 Second Amendment to Receivables Purchase Agreement, dated as of January 28, 2026, by and among Labcorp Receivables LLC, as seller, persons from time to time party hereto, as purchasers, PNC Bank National Association, as administrative agent, Laboratory Corporation of America Holdings, as Servicer, and PNC Capital Markets, as structuring agent (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 29, 2026). 10.2 Term Loan Credit Agreement dated as of March 20, 2026 among the Company, Wells Fargo Bank, N.A., as administrative agent, and lenders party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 20, 2026). 22.1* Subsidiary Issuers of Guaranteed Securities 31.1* Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) 31.2* Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) 32** Written Statement of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350) 101.INS* Inline XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH* Inline XBRL Taxonomy Extension Schema 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101) * filed herewith ** furnished herewith 31 TABLE OF CONTENTS SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LABCORP HOLDINGS INC. Registrant By: /s/ ADAM H. SCHECHTER Adam H. Schechter President and Chief Executive Officer (Principal Executive Officer) By: /s/ JULIA A. WANG Julia A. Wang Executive Vice President and Chief Financial Officer (Principal Financial Officer) Dated: May 4, 2026 32